almirall_logo

Dr Stephen Tyring, MD, PhD:

Treatment testimonial video

Transcript

Open
Close

Hello, this is Dr Steve Tyring in Houston, Texas.

I started prescribing KLISYRI® when it became available after having done the clinical trials that were published in the New England Journal of Medicine last year. And in those trials, we saw a good rate of clearance of the actinic keratoses, good compliance by the patients, and based upon observations in the trials, we started prescribing it as soon as it became commercially available.

Patients that benefit most from KLISYRI® are those that have more than just a couple of AKs. So, when they apply the five-day course of KLISYRI®, usually by the fifth day they will have some erythema. But if they have any pruritus or discomfort, it's usually quite mild and well tolerated. So, by the fifth day, they've completed the course and are usually very compliant. And when they come back, the majority of their AKs have cleared and patients generally are quite satisfied with the results.

When any fellow dermatologists who haven’t prescribed KLISYRI® ask me about my advice for treating AKs, my recommendations are to use field therapy for those patients that have more than just a couple of AKs and with KLISYRI®, after five days, the patients will have usually demonstrated good compliance and they will usually see a high rate of clearance. So, good compliance, good results, the short term and good results in the long term, are all the reasons that I recommend KLISYRI® to my patients for field therapy of their AKs.

INDICATION

KLISYRI is a microtubule inhibitor indicated for the topical treatment of actinic keratosis of the face or scalp

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Ophthalmic Adverse Reactions

KLISYRI may cause eye irritation. Avoid transfer of the drug into the eyes and to the periocular area during and after application. Wash hands immediately after application. If accidental exposure occurs, instruct patient to flush eyes with water and seek medical care as soon as possible

Local Skin Reactions

Local skin reactions, including severe reactions (erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration) in the treated area can occur after topical application of KLISYRI. Occlusion after topical application of KLISYRI is more likely to result in irritation. Avoid use until skin is healed from any previous drug, procedure, or surgical treatment.

ADVERSE REACTIONS

The most common adverse reactions (incidence ≥2%) were local skin reactions, application site pruritus, and application site pain.

Please see full Prescribing Information.

References: 1. Blauvelt A, Kempers S, Lain E, et al. Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis. N Engl J Med. 2021;384:512-520. 2. KLISYRI®. Prescribing information. Almirall, LLC.

KLISYRI® is a registered trademark of Almirall, LLC.
© 2005-2023
All rights reserved.
Almirall, LLC, 101 Lindenwood Drive, Ste 400, Malvern, PA 19355
US-TIRBA-2200051 02/2023

IMPORTANT SAFETY INFORMATION

INDICATION

KLISYRI is a microtubule inhibitor indicated for the topical field treatment of actinic keratosis on the face or scalp.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Ophthalmic Adverse Reactions

KLISYRI may cause eye irritation. Avoid transfer of the drug into the eyes and to the periocular area during and after application. Wash hands immediately after application. If accidental exposure occurs, instruct patient to flush eyes with water and seek medical care as soon as possible.

Local Skin Reactions

Local skin reactions, including severe reactions (erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration) in the treated area can occur after topical application of KLISYRI. Occlusion after topical application of KLISYRI is more likely to result in irritation. Avoid use until skin is healed from any previous drug, procedure, or surgical treatment.

ADVERSE REACTIONS

The most common adverse reactions (incidence ≥2%) were local skin reactions, application site pruritus, and application site pain.

Please see full Prescribing Information.

To report an adverse event or product complaint, call or email Medical Affairs and Customer Relations • Phone: 1-866-665-2782• Fax: 510-595-8183 •
Email: almirallmc@eversana.com